Russia has released the first batch of the Sputnik V vaccine against the Covid-19 coronavirus disease, the ANI news agency reported on Tuesday. On the other hand, Chinese firm Sinovac Biotech Ltd said its CoronaVac vaccine candidate appeared to be safe for the elderly based on preliminary results from an early to mid-stage trial.
In the United States, President Donald Trump has said the vaccine to treat the deadly disease could become available in October, while a new experimental Covid-19 vaccine originating from the University of Oxford has begun human trials in Australia in partnership. with the Serum Institute of India, the world’s largest vaccine manufacturer.
Follow the latest updates on coronavirus here
At a time when the global Covid-19 count has surpassed 27 million and the death toll from the disease is 892,880, here’s a look at the latest on the Covid-19 vaccines being developed around the world. .
— India: The Rohtak Graduate Institute (PGI) is scheduled to begin the phase 2 human clinical trial of Bharat Biotech’s vaccine candidate, based on an inactivated virus obtained by ICMR, on Wednesday.
“We obtained permission from Bharat Biotech to initiate a phase 2 human clinical trial of their vaccine. We have 300 volunteers, ranging in age from 12 to 65, of which the selection of 15 has been completed, ”Dr OP Kalra, Vice Chancellor of PGI Rohtak told the ANI news agency.
The Zydus Cadila candidate based on viral DNA is also in a second phase of testing, while the Oxford candidate vaccine developed by the Serum Institute of India is already in phase III testing in Maharashtra and some other states.
–Russia: Sputnik V, a Russian-developed vaccine against viral infection, has been released to civilian public circulation and regional deliveries are planned in the near future, the Russian Health Ministry said, quoted by ANI. He added that the vaccine has passed the necessary quality tests in the laboratories of the medical device regulator Roszdravnadzor.
–AustraliaAustralia expects to receive its first batches of a potential COVID-19 vaccine in January, its Prime Minister Scott Morrison said.
Additionally, a new vaccine devised by a British company SpyBiotech has begun enrolling volunteers in a phase I / II trial in Australia led by the Serum Institute, which will eventually enroll several hundred participants, said Sumi Biswas, the company’s chief executive. and a professor in the Nuffield Department of Medicine at Oxford.
Click here for full Covid-19 coverage
SpyBiotech has an exclusive license agreement with the Serum Institute for the vaccine. The institute reached a licensing agreement with AstraZeneca earlier this year to produce 1 billion doses of the Oxford injection developed by Gilbert.
–U.SUS President Donald Trump said in a briefing at the White House on Monday that a vaccine could be ready in October.
Three Covid-19 vaccines are undergoing end-phase or phase 3 clinical trials in the U.S. Each study is enrolling about 30,000 people who will receive two injections, three weeks apart, and then be monitored for infections by coronavirus and side effects for one week to two years.
Additionally, under a program Trump calls “Operation Warp Speed,” the goal is to have 300 million doses of a coronavirus vaccine in stock by January.
–China: The CoronaVac candidate from Chinese company Sinovac is being tested in Brazil and Indonesia in end-stage human trials to assess whether it is effective and safe enough to gain regulatory approvals for mass use. It has already been delivered to tens of thousands of people, including around 90% of Sinovac employees and their families, as part of China’s emergency vaccination plan to protect people facing high risk of infection.
.
